All In MedTech

Device Trial Radar · NCT02024464

Comparing Hydrus Microstent(TM) to the iStent for Lowering IOP in Glaucoma Patients Undergoing Cataract Surgery

A Prospective, Multicenter, Randomized Comparison of the Hydrus Microstent to the iStent for Lowering Intraocular Pressure in Glaucoma Patients Undergoing Cataract Surgery

Last checked: Nov 19, 2026Latest source record: Jul 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 306 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

306

Actual

Start

Aug 2011

Primary completion

Mar 2017

Study completion Aug 2018

Sponsor

Lead sponsor
Ivantis, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Dec 31, 2013

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
Who can join
All sexes, from 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial compares two implantable devices intended to lower the pressure inside the eye of glaucoma patients. One of the two devices will be implanted immediately following cataract surgery and the placement of a posterior chamber intra-ocular lens. Only one eye (study eye) will be implanted.

Conditions

  • Primary Open Angle Glaucoma
  • Pseudoexfoliative Glaucoma
  • Pigmentary Dispersion Glaucoma

Interventions

  • Hydrus MicrostentDevice

    Device inserted into Schlemm's canal to enhance aqueous flow from the anterior chamber.

  • iStent Trabecular Micro BypassDevice

    Device inserted into Schlemm's canal to enhance aqueous flow from the anterior chamber.

  • Cataract removal and intraocular lens (IOL) implantationProcedure

    Cataract removal with phacoemulsification using standard techniques, followed by implantation with a posterior-chamber IOL suitable for glaucoma subjects

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Unmedicated Mean Diurnal Intraocular Pressure (DIOP) at Month 12Time frame: Month 12: 8 am, 12 pm, 4 pm

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.